A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib

Affiliations

¹ Digestive Molecular Clinical Oncology Research Unit, Università degli Studi di Verona, Verona, Italy.
² Digestive Molecular Clinical Oncology Research Unit, Università degli Studi di Verona, Experimental Cancer Medicine Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. Electronic address: davide.melisi@univr.it.

Editorial

Silvia Pietrobono et al. Cell Mol Gastroenterol Hepatol. 2021.

. 2021;12(3):1151-1152.

doi: 10.1016/j.jcmgh.2021.06.005. Epub 2021 Jun 25.

¹ Digestive Molecular Clinical Oncology Research Unit, Università degli Studi di Verona, Verona, Italy.
² Digestive Molecular Clinical Oncology Research Unit, Università degli Studi di Verona, Experimental Cancer Medicine Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. Electronic address: davide.melisi@univr.it.

No abstract available

Comment on

TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
Xia S, Ji L, Tao L, Pan Y, Lin Z, Wan Z, Pan H, Zhao J, Cai L, Xu J, Cai X. Xia S, et al. Cell Mol Gastroenterol Hepatol. 2021;12(3):1121-1143. doi: 10.1016/j.jcmgh.2021.04.016. Epub 2021 May 5. Cell Mol Gastroenterol Hepatol. 2021. PMID: 33962073 Free PMC article.

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. - PubMed
1. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Haussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J., SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. - PubMed
1. Finn R.S., Qin S., Ikeda M., Galle P.R., Ducreux M., Kim T.Y., Kudo M., Breder V., Merle P., Kaseb A.O., Li D., Verret W., Xu D.Z., Hernandez S., Liu J., Huang C., Mulla S., Wang Y., Lim H.Y., Zhu A.X., Cheng A.L. IMbrave 150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–1905. - PubMed
1. Xia S., Ji L., Tao L. TAK1 is a novel target in hepatocellular carcinoma and contributes to sorafenib resistance. Cell Mol Gastroenterol Hepatol. 2021;12:1121–1143. - PMC - PubMed
1. Santoro R., Carbone C., Piro G., Chiao P.J., Melisi D. TAK-ing aim at chemoresistance: the emerging role of MAP3K7 as a target for cancer therapy. Drug Resist Updat. 2017;33-35:36–42. - PubMed